- Olema Oncology to Participate in Canaccord Genuity 2024 Horizons in Oncology Virtual Conference
- Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Olema Oncology Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Update
- Olema Oncology Announces Publication of Data Highlighting Palazestrant’s Ability to Inhibit Wild-Type and Mutant ER+ Breast Cancer Both as Monotherapy and in Combination with CDK4/6 Inhibitors
- Olema Oncology to Participate in Upcoming Investor Conferences
- Olema Oncology Nominates OP-3136, an Orally Bioavailable KAT6 Inhibitor, as a Development Candidate
- Olema Oncology to Present at 42nd Annual J.P. Morgan Healthcare Conference
- Olema Oncology Announces Palazestrant Demonstrates Attractive Combinability with CDK4/6 Inhibitors Ribociclib and Palbociclib in Phase 1b/2 Studies
- Olema Oncology to Present New Palazestrant Clinical Data in Combination with CDK4/6 Inhibitors at the 2023 San Antonio Breast Cancer Symposium (SABCS)
- Olema Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate Update
More ▼
Key statistics
On Thursday, Olema Pharmaceuticals Inc (OLMA:NSQ) closed at 9.90, 178.87% above the 52 week low of 3.55 set on Apr 18, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 10.64 |
---|---|
High | 10.76 |
Low | 9.78 |
Bid | 3.96 |
Offer | 12.00 |
Previous close | 9.90 |
Average volume | 640.25k |
---|---|
Shares outstanding | 55.91m |
Free float | 53.71m |
P/E (TTM) | -- |
Market cap | 553.56m USD |
EPS (TTM) | -2.16 USD |
Data delayed at least 15 minutes, as of Apr 18 2024 21:00 BST.
More ▼